Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or primary human data
PubMed 29515570 · doi:10.3389/fimmu.2018.00226
What was done
This narrative review summarizes established risk factors (such as prematurity and young age at infection) alongside emerging mechanisms (including epigenetic factors, microbiome composition, and metabolic profiles) that influence immune development and susceptibility to severe respiratory syncytial virus (RSV) infection.
What was found
The abstract reports no numerical values, effect estimates, or statistical data. It describes RSV as infecting virtually all children by 2 years of age and being the leading global cause of infant hospitalization, noting that severe lower respiratory tract infection increases the risk of subsequent childhood wheezing and may occur via intrinsic and extrinsic immune-altering factors even in infants without standard risk factors.
Why it matters
It emphasizes the role of the microbiome, metabolites, and immune development in severe RSV pathogenesis and post-viral wheeze beyond traditional clinical risk factors.
Limits
The abstract provides no original empirical data, systematic search criteria, or quantitative risk estimates. Potential confounding, causal pathways, and specific cohort characteristics are not detailed.
Cited by
- supports Respiratory syncytial virus (RSV) infects the respiratory tract of most children by 2 years of age.